221 related articles for article (PubMed ID: 25943234)
1. The relative benefits and costs of solid phase bead technology to detect preformed donor specific antihuman leukocyte antigen antibodies in determining suitability for kidney transplantation.
Nguyen HT; Lim WH; Craig JC; Chapman JR; Lord SJ; Howard K; Wong G
Transplantation; 2015 May; 99(5):957-64. PubMed ID: 25943234
[TBL] [Abstract][Full Text] [Related]
2. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
[TBL] [Abstract][Full Text] [Related]
3. Analysis of preformed donor-specific anti-HLA antibodies characteristics for prediction of antibody-mediated rejection in kidney transplantation.
Malheiro J; Tafulo S; Dias L; Martins LS; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
Transpl Immunol; 2015 Mar; 32(2):66-71. PubMed ID: 25661873
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation.
Caro-Oleas JL; González-Escribano MF; González-Roncero FM; Acevedo-Calado MJ; Cabello-Chaves V; Gentil-Govantes MÁ; Núñez-Roldán A
Nephrol Dial Transplant; 2012 Mar; 27(3):1231-8. PubMed ID: 21810767
[TBL] [Abstract][Full Text] [Related]
5. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
Lee PC; Ozawa M
Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?
Crespo M; Torio A; Mas V; Redondo D; Pérez-Sáez MJ; Mir M; Faura A; Guerra R; Montes-Ares O; Checa MD; Pascual J
Transpl Immunol; 2013 Dec; 29(1-4):28-33. PubMed ID: 23907088
[TBL] [Abstract][Full Text] [Related]
7. Deceased donor kidney transplantation across donor-specific antibody barriers: predictors of antibody-mediated rejection.
Schwaiger E; Eskandary F; Kozakowski N; Bond G; Kikić Ž; Yoo D; Rasoul-Rockenschaub S; Oberbauer R; Böhmig GA
Nephrol Dial Transplant; 2016 Aug; 31(8):1342-51. PubMed ID: 27190362
[TBL] [Abstract][Full Text] [Related]
8. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation.
Tait BD; Süsal C; Gebel HM; Nickerson PW; Zachary AA; Claas FH; Reed EF; Bray RA; Campbell P; Chapman JR; Coates PT; Colvin RB; Cozzi E; Doxiadis II; Fuggle SV; Gill J; Glotz D; Lachmann N; Mohanakumar T; Suciu-Foca N; Sumitran-Holgersson S; Tanabe K; Taylor CJ; Tyan DB; Webster A; Zeevi A; Opelz G
Transplantation; 2013 Jan; 95(1):19-47. PubMed ID: 23238534
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of Luminex-based donor-specific antibody mean fluorescence intensity values with complement-dependent cytotoxicity & flow crossmatch results in live donor renal transplantation.
Baranwal AK; Bhat DK; Goswami S; Agarwal SK; Kaur G; Kaur J; Mehra N
Indian J Med Res; 2017 Feb; 145(2):222-228. PubMed ID: 28639599
[TBL] [Abstract][Full Text] [Related]
10. Human leukocyte antigen antibody-incompatible renal transplantation: excellent medium-term outcomes with negative cytotoxic crossmatch.
Higgins R; Lowe D; Hathaway M; Williams C; Lam FT; Kashi H; Tan LC; Imray C; Fletcher S; Chen K; Krishnan N; Hamer R; Daga S; Edey M; Zehnder D; Briggs D
Transplantation; 2011 Oct; 92(8):900-6. PubMed ID: 21968524
[TBL] [Abstract][Full Text] [Related]
11. Pretransplant donor-specific HLA antibodies detected by single antigen bead flow cytometry: risk factors and outcomes after kidney transplantation.
Kanter Berga J; Sancho Calabuig A; Gavela Martinez E; Puig Alcaraz N; Beltran Catalan S; Avila Bernabeu A; Crespo Albiach J; Montoro JA; Pallardo Mateu LM
Transplant Proc; 2012 Nov; 44(9):2529-31. PubMed ID: 23146444
[TBL] [Abstract][Full Text] [Related]
12. Preformed Donor-Specific HLA Antibodies in Living and Deceased Donor Transplantation: A Multicenter Study.
Ziemann M; Altermann W; Angert K; Arns W; Bachmann A; Bakchoul T; Banas B; von Borstel A; Budde K; Ditt V; Einecke G; Eisenberger U; Feldkamp T; Görg S; Guthoff M; Habicht A; Hallensleben M; Heinemann FM; Hessler N; Hugo C; Kaufmann M; Kauke T; Koch M; König IR; Kurschat C; Lehmann C; Marget M; Mühlfeld A; Nitschke M; Pego da Silva L; Quick C; Rahmel A; Rath T; Reinke P; Renders L; Sommer F; Spriewald B; Staeck O; Stippel D; Süsal C; Thiele B; Zecher D; Lachmann N
Clin J Am Soc Nephrol; 2019 Jul; 14(7):1056-1066. PubMed ID: 31213508
[TBL] [Abstract][Full Text] [Related]
13. Pre-transplant donor specific anti-HLA antibody is associated with antibody-mediated rejection, progressive graft dysfunction and patient death.
Fidler SJ; Irish AB; Lim W; Ferrari P; Witt CS; Christiansen FT
Transpl Immunol; 2013 Jun; 28(4):148-53. PubMed ID: 23665534
[TBL] [Abstract][Full Text] [Related]
14. Virtual crossmatch by identification of donor-specific anti-human leukocyte antigen antibodies by solid-phase immunoassay: a 30-month analysis in living donor kidney transplantation.
Morris GP; Phelan DL; Jendrisak MD; Mohanakumar T
Hum Immunol; 2010 Mar; 71(3):268-73. PubMed ID: 20074605
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value and cost-effectiveness of different screening strategies for HLA antibodies prior to kidney transplantation.
Ziemann M; Schönemann C; Bern C; Lachmann N; Nitschke M; Fricke L; Görg S
Clin Transplant; 2012; 26(4):644-56. PubMed ID: 22432638
[TBL] [Abstract][Full Text] [Related]
16. Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant?
Gupta A; Iveson V; Varagunam M; Bodger S; Sinnott P; Thuraisingham RC
Transplantation; 2008 Apr; 85(8):1200-4. PubMed ID: 18431242
[TBL] [Abstract][Full Text] [Related]
17. Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts.
Lawrence C; Willicombe M; Brookes PA; Santos-Nunez E; Bajaj R; Cook T; Roufosse C; Taube D; Warrens AN
Transplantation; 2013 Jan; 95(2):341-6. PubMed ID: 23197178
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of anti-HLA donor-specific antibodies detected by Luminex assay in the development of rejection after renal transplantation.
Caro-Oleas JL; González-Escribano MF; Gentil-Govantes MÁ; Acevedo MJ; González-Roncero FM; Blanco GB; Núñez-Roldán A
Transplantation; 2012 Aug; 94(4):338-44. PubMed ID: 22814330
[TBL] [Abstract][Full Text] [Related]
19. Epitope Analysis Aids in Transplant Decision Making by Determining the Clinical Relevance of Apparent Pre-Transplant Donor Specific Antibodies (DSA).
Pandey S; Harville TO
Ann Clin Lab Sci; 2019 Jan; 49(1):50-56. PubMed ID: 30814077
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts.
Cooper JE; Gralla J; Chan L; Wiseman AC
Clin Transpl; 2011; ():359-64. PubMed ID: 22755431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
